Maryland Oncology Hematology

The trials here

What the 8 trials at this site are about, from their registry records.

Conditions

• Gastric and oesophageal cancer3 trials
• Lung cancer3 trials
• Prostate cancer3 trials
• Bladder cancer2 trials
• Cervical cancer2 trials
• Colorectal cancer2 trials
• Endometrial cancer2 trials
• Kidney cancer2 trials
• Melanoma2 trials
• Ovarian cancer2 trials
• Triple-negative breast cancer2 trials
• Chronic lymphocytic leukaemia1 trial
• and 6 more

Phase

• Phase 13 trials
• Phase 33 trials
• Phase 22 trials

Status

• Active, not recruiting3 trials
• Recruiting3 trials
• Completed2 trials

Lead sponsor

• Hoffmann-La Roche1 trial
• Ipsen1 trial
• Nurix Therapeutics, Inc.1 trial
• ORIC Pharmaceuticals1 trial
• Pieris Pharmaceuticals, Inc.1 trial
• and 3 more

Running trials

• Recruiting

  A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)

  NCT07218146· Phase 3· Zai Lab (Shanghai) Co., Ltd.· Source

• Recruiting

  A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)

  NCT07221500· Phase 2· Nurix Therapeutics, Inc.· Source

• Recruiting

  Study of ORIC-944 in Patients With Metastatic Prostate Cancer

  NCT05413421· Phase 1· ORIC Pharmaceuticals· Source

  Contact: ORIC Clinical

• Active, not recruiting

  Cinrebafusp Alfa in Combination With Ramucirumab and Paclitaxel in HER2-High Gastric or GEJ Adenocarcinoma and in Combination With Tucatinib in HER2-Low Gastric or GEJ Andenocarinoma

  NCT05190445· Phase 2· Pieris Pharmaceuticals, Inc.· Source

• Active, not recruiting

  A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer)

  NCT04546009· Phase 3· Hoffmann-La Roche· Source

• Active, not recruiting

  TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers

  NCT04485013· Phase 1· Tizona Therapeutics, Inc· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Chronic lymphocytic leukaemia1 recruiting
• Lung cancer1 recruiting
• Prostate cancer1 recruiting

Closed trials

• Completed

  A Study to Assess the Effectiveness and Safety of Irinotecan Liposome Injection, 5-fluorouracil/Leucovorin Plus Oxaliplatin in Patients Not Previously Treated for Metastatic Pancreatic Cancer, Compared to Nab-paclitaxel+Gemcitabine Treatment

  NCT04083235· Phase 3· Ipsen· Source

• Completed

  Phase I Dose Escalation Study for VIP152 in Patients With Advanced Cancer

  NCT02635672· Phase 1· Vincerx Pharma, Inc.· Source